O	0	10	Randomized
O	11	16	Phase
O	17	19	II
O	20	25	Study
O	26	36	Evaluating
B-intervention	37	48	Palbociclib
I-intervention	49	51	in
I-intervention	52	60	Addition
I-intervention	61	63	to
I-intervention	64	73	Letrozole
O	74	76	as
O	77	88	Neoadjuvant
O	89	96	Therapy
O	97	99	in
O	100	108	Estrogen
O	109	117	Receptor
O	117	118	-
O	118	126	Positive
O	127	132	Early
O	133	139	Breast
O	140	146	Cancer
O	146	147	:
O	148	154	PALLET
O	155	160	Trial
O	160	161	.

O	162	166	CDK4
O	166	167	/
O	167	168	6
O	169	179	inhibitors
O	180	183	are
O	184	188	used
O	189	191	to
O	192	197	treat
O	198	206	estrogen
O	207	215	receptor
O	216	217	(
O	217	219	ER
O	219	220	)
O	220	221	-
O	221	229	positive
O	230	240	metastatic
O	241	247	breast
O	248	254	cancer
O	255	256	(
O	256	258	BC
O	258	259	)
O	260	262	in
O	263	274	combination
O	275	279	with
O	280	289	endocrine
O	290	297	therapy
O	297	298	.

O	299	305	PALLET
O	306	308	is
O	309	310	a
O	311	316	phase
O	317	319	II
O	320	330	randomized
O	331	336	trial
O	337	341	that
O	342	351	evaluated
O	352	355	the
O	356	363	effects
O	364	366	of
O	367	378	combination
O	379	390	palbociclib
O	391	395	plus
O	396	405	letrozole
O	406	408	as
O	409	420	neoadjuvant
O	421	428	therapy
O	428	429	.

B-eligibility	430	444	Postmenopausal
I-eligibility	445	450	women
I-eligibility	451	455	with
I-eligibility	456	458	ER
I-eligibility	458	459	-
I-eligibility	459	467	positive
I-eligibility	468	475	primary
I-eligibility	476	478	BC
I-eligibility	479	482	and
I-eligibility	483	489	tumors
I-eligibility	490	497	greater
I-eligibility	498	502	than
I-eligibility	503	505	or
I-eligibility	506	511	equal
I-eligibility	512	514	to
I-eligibility	515	516	2
I-eligibility	516	517	.
I-eligibility	517	518	0
I-eligibility	519	521	cm
O	522	526	were
O	527	535	randomly
O	536	544	assigned
O	545	546	3
O	546	547	:
O	547	548	2
O	548	549	:
O	549	550	2
O	550	551	:
O	551	552	2
O	553	555	to
B-control	556	565	letrozole
O	566	567	(
O	567	568	2
O	568	569	.
O	569	570	5
O	571	573	mg
O	573	574	/
O	574	575	d
O	575	576	)
O	577	580	for
O	581	583	14
O	584	589	weeks
O	590	591	(
O	591	592	A
O	592	593	)
O	593	594	;
O	595	604	letrozole
O	605	608	for
O	609	610	2
O	611	616	weeks
O	616	617	,
O	618	622	then
O	623	634	palbociclib
O	635	639	plus
O	640	649	letrozole
O	650	652	to
O	653	655	14
O	656	661	weeks
O	662	663	(
O	663	664	B
O	664	665	)
O	665	666	;
O	667	678	palbociclib
O	679	682	for
O	683	684	2
O	685	690	weeks
O	690	691	,
O	692	696	then
O	697	708	palbociclib
O	709	713	plus
O	714	723	letrozole
O	724	726	to
O	727	729	14
O	730	735	weeks
O	736	737	(
O	737	738	C
O	738	739	)
O	739	740	;
O	741	743	or
O	744	755	palbociclib
O	756	760	plus
O	761	770	letrozole
O	771	774	for
O	775	777	14
O	778	783	weeks
O	783	784	.

O	785	796	Palbociclib
O	797	800	125
O	801	803	mg
O	803	804	/
O	804	805	d
O	806	809	was
O	810	822	administered
O	823	829	orally
O	830	832	on
O	833	834	a
O	835	837	21
O	837	838	-
O	838	842	days
O	842	843	-
O	843	845	on
O	845	846	,
O	847	848	7
O	848	849	-
O	849	853	days
O	853	854	-
O	854	857	off
O	858	866	schedule
O	866	867	.

O	868	872	Core
O	872	873	-
O	873	876	cut
O	877	885	biopsies
O	886	890	were
O	891	896	taken
O	897	899	at
O	900	908	baseline
O	909	912	and
O	913	914	2
O	915	918	and
O	919	921	14
O	922	927	weeks
O	927	928	.

O	929	938	Coprimary
O	939	942	end
O	943	949	points
O	950	953	for
O	954	963	letrozole
O	964	970	versus
O	971	982	palbociclib
O	983	987	plus
O	988	997	letrozole
O	998	1004	groups
O	1005	1006	(
O	1006	1007	A
O	1008	1009	v
O	1010	1011	B
O	1012	1013	+
O	1014	1015	C
O	1016	1017	+
O	1018	1019	D
O	1019	1020	)
O	1021	1025	were
B-outcome-Measure	1026	1032	change
I-outcome-Measure	1033	1035	in
I-outcome-Measure	1036	1038	Ki
I-outcome-Measure	1038	1039	-
I-outcome-Measure	1039	1041	67
O	1042	1043	(
O	1043	1050	protein
O	1051	1058	encoded
O	1059	1061	by
O	1062	1065	the
O	1067	1072	MKI67
O	1073	1077	gene
O	1077	1078	;
O	1079	1099	immunohistochemistry
O	1099	1100	)
O	1101	1108	between
O	1109	1117	baseline
O	1118	1121	and
O	1122	1124	14
O	1125	1130	weeks
O	1131	1134	and
O	1135	1143	clinical
O	1144	1152	response
O	1153	1154	(
O	1154	1161	ordinal
O	1162	1165	and
O	1166	1176	ultrasound
O	1176	1177	)
O	1178	1183	after
O	1184	1186	14
O	1187	1192	weeks
O	1192	1193	.

O	1194	1202	Complete
O	1203	1207	cell
O	1207	1208	-
O	1208	1213	cycle
O	1214	1220	arrest
O	1221	1224	was
O	1225	1232	defined
O	1233	1235	as
O	1236	1238	Ki
O	1238	1239	-
O	1239	1241	67
O	1242	1246	less
O	1247	1251	than
O	1252	1254	or
O	1255	1260	equal
O	1261	1263	to
O	1264	1265	2
O	1265	1266	.
O	1266	1267	7
O	1267	1268	%
O	1268	1269	.

O	1270	1279	Apoptosis
O	1280	1283	was
O	1284	1297	characterized
O	1298	1300	by
O	1301	1308	cleaved
O	1309	1313	poly
O	1314	1315	(
O	1315	1318	ADP
O	1318	1319	-
O	1319	1325	ribose
O	1325	1326	)
O	1327	1337	polymerase
O	1337	1338	.

B-total-participants	1339	1344	Three
I-total-participants	1345	1352	hundred
I-total-participants	1353	1358	seven
O	1359	1367	patients
O	1368	1372	were
O	1373	1382	recruited
O	1382	1383	.

B-outcome	1384	1392	Clinical
I-outcome	1393	1401	response
O	1402	1405	was
O	1406	1409	not
O	1410	1423	significantly
O	1424	1433	different
O	1434	1441	between
O	1442	1453	palbociclib
O	1454	1458	plus
O	1459	1468	letrozole
O	1469	1472	and
O	1473	1482	letrozole
O	1483	1489	groups
O	1490	1491	(
O	1492	1493	P
O	1494	1495	=
O	1496	1497	.
O	1497	1499	20
O	1499	1500	;
B-outcome	1501	1509	complete
I-outcome	1510	1518	response
I-outcome	1519	1520	+
I-outcome	1521	1528	partial
I-outcome	1529	1537	response
O	1537	1538	,
B-iv-bin-percent	1539	1541	54
I-iv-bin-percent	1541	1542	.
I-iv-bin-percent	1542	1543	3
I-iv-bin-percent	1543	1544	%
O	1545	1546	v
B-cv-bin-percent	1547	1549	49
I-cv-bin-percent	1549	1550	.
I-cv-bin-percent	1550	1551	5
I-cv-bin-percent	1551	1552	%
O	1552	1553	)
O	1553	1554	,
O	1555	1558	and
B-outcome	1559	1570	progressive
I-outcome	1571	1578	disease
O	1579	1582	was
B-iv-bin-percent	1583	1584	3
I-iv-bin-percent	1584	1585	.
I-iv-bin-percent	1585	1586	2
I-iv-bin-percent	1586	1587	%
O	1588	1594	versus
B-cv-bin-percent	1595	1596	5
I-cv-bin-percent	1596	1597	.
I-cv-bin-percent	1597	1598	4
I-cv-bin-percent	1598	1599	%
O	1599	1600	,
O	1601	1613	respectively
O	1613	1614	.

B-outcome	1615	1621	Median
I-outcome	1622	1625	log
I-outcome	1625	1626	-
I-outcome	1626	1630	fold
I-outcome	1631	1637	change
I-outcome	1638	1640	in
I-outcome	1641	1643	Ki
I-outcome	1643	1644	-
I-outcome	1644	1646	67
O	1647	1650	was
O	1651	1658	greater
O	1659	1663	with
O	1664	1675	palbociclib
O	1676	1680	plus
O	1681	1690	letrozole
O	1691	1699	compared
O	1700	1704	with
O	1705	1714	letrozole
O	1715	1716	(
B-iv-cont-median	1716	1717	-
I-iv-cont-median	1717	1718	4
I-iv-cont-median	1718	1719	.
I-iv-cont-median	1719	1720	1
O	1721	1722	v
B-cv-cont-median	1723	1724	-
I-cv-cont-median	1724	1725	2
I-cv-cont-median	1725	1726	.
I-cv-cont-median	1726	1727	2
O	1727	1728	;
O	1729	1730	P
O	1731	1732	<
O	1733	1734	.
O	1734	1737	001
O	1737	1738	)
O	1739	1741	in
O	1742	1745	the
O	1746	1749	190
O	1750	1759	evaluable
O	1760	1768	patients
O	1769	1770	(
O	1770	1772	61
O	1772	1773	.
O	1773	1774	9
O	1774	1775	%
O	1775	1776	)
O	1776	1777	,
O	1778	1791	corresponding
O	1792	1794	to
O	1795	1796	a
O	1797	1806	geometric
O	1807	1811	mean
O	1812	1818	change
O	1819	1821	of
O	1822	1823	-
O	1823	1825	97
O	1825	1826	.
O	1826	1827	4
O	1827	1828	%
O	1829	1835	versus
O	1836	1837	-
O	1837	1839	88
O	1839	1840	.
O	1840	1841	5
O	1841	1842	%
O	1842	1843	.

O	1844	1848	More
O	1849	1857	patients
O	1858	1860	on
O	1861	1872	palbociclib
O	1873	1877	plus
O	1878	1887	letrozole
B-outcome	1888	1896	achieved
I-outcome	1897	1905	complete
I-outcome	1906	1910	cell
I-outcome	1910	1911	-
I-outcome	1911	1916	cycle
I-outcome	1917	1923	arrest
O	1924	1925	(
B-iv-bin-percent	1925	1927	90
I-iv-bin-percent	1927	1928	%
O	1929	1930	v
B-cv-bin-percent	1931	1933	59
I-cv-bin-percent	1933	1934	%
O	1934	1935	;
O	1936	1937	P
O	1938	1939	<
O	1940	1941	.
O	1941	1944	001
O	1944	1945	)
O	1945	1946	.

B-outcome	1947	1953	Median
I-outcome	1954	1957	log
I-outcome	1957	1958	-
I-outcome	1958	1962	fold
I-outcome	1963	1969	change
I-outcome	1970	1971	(
I-outcome	1971	1982	suppression
I-outcome	1982	1983	)
I-outcome	1984	1986	of
I-outcome	1987	1994	cleaved
I-outcome	1995	1999	poly
I-outcome	2000	2001	(
I-outcome	2001	2004	ADP
I-outcome	2004	2005	-
I-outcome	2005	2011	ribose
I-outcome	2011	2012	)
I-outcome	2013	2023	polymerase
O	2024	2027	was
O	2028	2035	greater
O	2036	2040	with
O	2041	2052	palbociclib
O	2053	2057	plus
O	2058	2067	letrozole
O	2068	2074	versus
O	2075	2084	letrozole
O	2085	2086	(
B-iv-cont-median	2086	2087	-
I-iv-cont-median	2087	2088	0
I-iv-cont-median	2088	2089	.
I-iv-cont-median	2089	2091	80
O	2092	2093	v
B-cv-cont-median	2094	2095	-
I-cv-cont-median	2095	2096	0
I-cv-cont-median	2096	2097	.
I-cv-cont-median	2097	2099	42
O	2099	2100	;
O	2101	2102	P
O	2103	2104	<
O	2105	2106	.
O	2106	2109	001
O	2109	2110	)
O	2110	2111	.

O	2112	2116	More
O	2117	2125	patients
O	2126	2129	had
B-outcome	2130	2135	grade
I-outcome	2136	2137	3
I-outcome	2138	2140	or
I-outcome	2141	2148	greater
I-outcome	2149	2157	toxicity
O	2158	2160	on
O	2161	2172	palbociclib
O	2173	2177	plus
O	2178	2187	letrozole
O	2188	2189	(
B-iv-bin-percent	2189	2191	49
I-iv-bin-percent	2191	2192	.
I-iv-bin-percent	2192	2193	8
I-iv-bin-percent	2193	2194	%
O	2195	2196	v
B-cv-bin-percent	2197	2199	17
I-cv-bin-percent	2199	2200	.
I-cv-bin-percent	2200	2201	0
I-cv-bin-percent	2201	2202	%
O	2202	2203	;
O	2204	2205	P
O	2206	2207	<
O	2208	2209	.
O	2209	2212	001
O	2212	2213	)
O	2214	2220	mainly
O	2221	2228	because
O	2229	2231	of
O	2232	2244	asymptomatic
O	2245	2256	neutropenia
O	2256	2257	.

O	2258	2264	Adding
O	2265	2276	palbociclib
O	2277	2279	to
O	2280	2289	letrozole
O	2290	2303	significantly
O	2304	2312	enhanced
O	2313	2316	the
O	2317	2328	suppression
O	2329	2331	of
O	2332	2341	malignant
O	2342	2346	cell
O	2347	2360	proliferation
O	2361	2362	(
O	2362	2364	Ki
O	2364	2365	-
O	2365	2367	67
O	2367	2368	)
O	2369	2371	in
O	2372	2379	primary
O	2380	2382	ER
O	2382	2383	-
O	2383	2391	positive
O	2392	2394	BC
O	2394	2395	,
O	2396	2399	but
O	2400	2403	did
O	2404	2407	not
O	2408	2416	increase
O	2417	2420	the
O	2421	2429	clinical
O	2430	2438	response
O	2439	2443	rate
O	2444	2448	over
O	2449	2451	14
O	2452	2457	weeks
O	2457	2458	,
O	2459	2464	which
O	2465	2468	was
O	2469	2477	possibly
O	2478	2485	related
O	2486	2488	to
O	2489	2490	a
O	2491	2501	concurrent
O	2502	2511	reduction
O	2512	2514	in
O	2515	2524	apoptosis
O	2524	2525	.
